Bridgett Ghetian

Bridgett Ghetian has accumulated extensive experience in the pharmaceutical industry with a focus on oncology and specialty pharmaceuticals. Currently serving as a Key Account Manager at Invivyd since April 2024, Bridgett launched Pemgarda, a monoclonal antibody for the pre-exposure prophylaxis of Covid-19 in immunocompromised patients. Prior to this role, Bridgett was an Oncology Account Manager at MorphoSys, specializing in immunotherapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Additional experience includes serving as an Oncology Territory Manager at Takeda Oncology, where Bridgett surpassed sales quotas for key products, and as an Executive Oncology Account Specialist at Teva Pharmaceuticals, achieving significant sales growth and rankings. Earlier career roles involved sales in CNS and respiratory products as well as account executive positions in security and telecommunications. Educational background includes a Bachelor's degree in Kinesiology from San Diego State University.